

# *Insufficienza aortica*

*La fisiopatologia, i  
metodi di valutazione  
della gravità del rigurgito,  
la funzione ventricolare  
sinistra ed il timing  
operatorio nelle fasce di  
età avanzate*



# *Insufficienza aortica*



- *Fisiopatologia*

*Gravità del rigurgito*

*Funzione ventricolare sinistra*

*Timing chirurgico*

# ***IAo cronica severa***




# *Fisiopatologia (1)*

- *Incremento del volume telediastolico e dello stress di parete del VS*
- *Aumentato precarico e postcarico del ventricolo sinistro*
- *Sovraccarico di volume e di pressione del ventricolo sinistro*




# Dilatazione / ipertrofia del VS

09/10/2012 17:27:13



09/10/2012 17:32:15



# *Fisiopatologia (2)*

- ***Combinazione dilatazione/ipertrofia (remodeling “efficiente” del VS)***
- ***Incremento dello stroke volume***
- ***Mantenimento di un’ adeguata gittata sistolica e di una normale frazione d’ eiezione del VS in assenza di significativo incremento delle pressioni di riempimento (incremento della compliance ventricolare)***





# *Fisiopatologia (3)*

**“Compensazione funzionale” bilancio tra:**

- *Eccesso di postcarico*
- *Riserva di precarico*
- *Ipertrofia ventricolare sinistra*



# ***IAo cronica severa***



# ***Fisiopatologia (4)***

## ***Progressione della malattia***

***Progressivo incremento del volume telediastolico del VS non più adeguatamente compensato dall' incremento dello spessore parietale***





***Incremento dello stress parietale***





***Afterload mismatch***



***Disfunzione sistolica del VS***



# Myocardial fibrosis





**Azevedo CF et al. J Am Coll Cardiol 2010; 56: 278-87**

# Disfunzione VS

TA AK

GUAD 50 COMP 70  
37HZ18CM  
2/0/A/H4  
94BPM  
0:48:49  
07 GIU 05  
11:29:48

MI:1.6  
S3 1.6/3.2  
Osp. Cardiologico  
G.M.Lancisi  
adulti mod




P E R  
1.6 3.2

TA AK

MI:1.2  
S3 1.6/3.2  
07 GIU 05  
12:12:11  
0/0/C/H4  
Osp. Cardiologico  
G.M.Lancisi  
adulti mod  
0:48:49  
GUAD 50  
COMP 70  
82BPM

12CM  
13HZ




P E R  
1.6 3.2

TA AK

MI:1.7  
S3 1.6/3.2  
07 GIU 05  
11:39:42  
0/0/C/H4  
Osp. Cardiologico  
G.M.Lancisi  
adulti mod  
0:48:49  
GUAD 50  
COMP 70  
84BPM

17CM  
25HZ



P E R  
1.6 3.2



# Relazione DVS-sintomi

**TABLE 1. Baseline Characteristics of 450 Patients Who Underwent AVR for AR With Baseline EF Measurement**

	LoEF EF <35%	MedE EF 35%–50%	NI EF EF ≥50%	P
No.	43	134	273	...
Female sex, %	19	23	22	0.82
Age, y	58±14	58±15	56±16	0.22
Associated CABG, %	21	25	21	0.63
CAD, %	22	31	23	0.12
CCS class III–IV, %	16	6	9	0.60
Atrial fibrillation, %	23	16	14	0.28
Hypertension, %	35	31	34	0.78
Creatinine, %	1.16±0.26	1.17±0.37	1.24±0.64	0.43
Diabetes, %	16	6	2	0.0002
NYHA class III–IV, %	58	49	29	<0.0001

**A large proportion of patients had *no symptoms* in the **LoEF** group (28 %) similar to the **MedEF** (30 %,  $p = 0.85$ ) or **NIEF** group (37 %,  $p = 0.31$ ).**




# Natural history of asymptomatic AR

<b>Study</b>	<b>Number of patients</b>	<b>Mean FU (yr)</b>	<b>Progression to symptoms, death or LV dysfunction rate/yr (%)</b>	<b>Progression to asymptomatic LV dysfunction rate/yr (%)</b>	<b>Mortality (number of patients)</b>
<i>Bonow (1983, 1991)</i>	104	8.0	3.8	0.5	2
<i>Scognamiglio (1986)</i>	30	4.7	2.1	2.1	0
<i>Siemienczuk (1989)</i>	50	3.7	4.0	0.5	0
<i>Scognamiglio (1994)</i>	74	6.0	5.7	3.4	0
<i>Tornos (1995)</i>	101	4.6	3.0	1.3	0
<i>Ishii (1996)</i>	27	14.2	3.6	--	0
<i>Borer (1998)</i>	104	7.3	6.2	0.9	4
<i>Tarasoutchi (2003)</i>	72	10.0	4.7	0.1	0
<i>Evangelista (2005)</i>	31	7.0	3.6	--	1
	<b>593</b>	<b>6.6</b>	<b>4.3</b>	<b>1.2</b>	<b>0.18 %/y</b>

**Età media: 39 anni**

# Natural history of asymptomatic AR

104 patients (mean age: 36 years)



Mean FU: 8 years

Sudden death: 2

Symptoms: 19

Asymptomatic LVD: 4

At 11 years  $58 \pm 9$  % of the patients were alive and asymptomatic with normal LV function



# *Mortality and morbidity of AR*

- *246 pazienti con insufficienza aortica III/IV - IV/IV*
- *192 maschi (78 %); età media: **56 ± 19 anni***
- *“Conservative management” (1985-1994)*
- *Follow-up medio : **7 ± 3 anni***

*Entro 10 anni: morte o necessità di chirurgia **nel 75 % dei pazienti** ed eventi cardiovascolari\* nell' 83 % dei pazienti.*

*\* morte CV, chirurgia, scompenso, dissezione aortica, tromboembolia, fibrillazione atriale, endocardite*

***Dujardin KS et al.: Circulation 1999; 99: 1851-7***



# *Indicazione chirurgica*

*81 pazienti (età media: 60 a.)*

<i>Sintomi:</i>	<i>38</i>
<i>Disfunzione o dilatazione VS:</i>	<i>17</i>
<i>Aneurisma aortico:</i>	<i>11</i>
<i>Endocardite infettiva:</i>	<i>3</i>
<i>Preferenza medico/paz:</i>	<i>11</i>
<i>Dissezione aortica:</i>	<i>1</i>



# *Insufficienza aortica*

## *Fisiopatologia*

- ***Gravità del rigurgito***

## *Funzione ventricolare sinistra*

## *Timing chirurgico*

# *Gravità dell' insufficienza aortica*

- ***Valutazione poliparametrica***
  - ***Integrazione di parametri:***
    - ***Qualitativi***
    - ***Semiquantitativi***
    - ***Quantitativi***


***Almeno 2 parametri concordanti !***



# *Insufficienza aortica severa*

*Difetto di coaptazione visualizzabile con ECO 2D*


23/05/2012 12:22:31



68  
HR


# *Insufficienza aortica cronica severa*

## *Dilatazione del ventricolo sinistro*



# Estensione del jet

**Parametro non raccomandato per la quantificazione**




- **Valutazione visiva iniziale**
- **Debole correlazione con la gravità dell' IAO**


## **Limiti:**

- **Fattori tecnici (gain, PRF)**
- **Jet eccentrici**
- **Fattori emodinamici ( gradiente ventricolo-aortico, compliance del VS)**

# Analisi del jet



# Ampiezza del jet



# Ampiezza del jet

**$< 0.25$**



***Insufficienza  
aortica lieve***

**ZONA  
GRIGIA**

**$\geq 0.65$**



***Insufficienza  
aortica severa***

# Ampiezza del jet

## **Vantaggi:**


- *Parametro semplice*
- *Rapido screening della gravità*
- *Specificità dei cut-off di IAo severa e lieve*

## **Limiti:**

- *Ampia zona grigia*
- *Jet eccentrici*
- *Orifizio di rigurgito irregolare*



# Vena contracta



# Vena contracta

**< 3 mm**

**3-6 mm**

**> 6 mm**



**Insufficienza  
aortica lieve**

**Insufficienza  
aortica moderata ?**

**Insufficienza  
aortica severa**




# *Vena contracta*

## *Limiti*

- *Valori intermedi richiedono l'utilizzazione di altri metodi diagnostici*
- *Piccolo valore numerico (errore %)*
- *Assunzione di orifizio circolare*
- *Jet multipli*
- *Jet marcatamente eccentrici*

# Vena contracta

**Orifizio di rigurgito irregolare**



# Vena contracta

## Vantaggi

- *Parametro semplice e riproducibile*
- *Specificità dei cut-off di LAo severa e lieve*
- *Migliore capacità discriminante rispetto agli altri parametri semiquantitativi*
- *Correlazione con la valutazione quantitativa*
- *Scarsamente influenzata da fattori emodinamici*


# Jet multipli

MI: 1.2 TIS: 1.1  
S3  
30 NOV 10  
13:31:25  
2/8/C/12/A  
R.O. G.M. LANCISI  
LICI  
Adulti  
BE CG



0:19:07  
GUAD 50  
COMP 70  
82BPM

17CM  
12HZ


P  $\frac{E}{R}$   
1.6 3.2



# Inversione diastolica



# Inversione diastolica





**Inversione diastolica del flusso in aorta discendente prossimale con velocità telediastolica > 20 cm/sec: elevata specificità per insufficienza aortica severa**

- Compliance aortica
- Frequenza cardiaca
- Insufficienza aortica acuta



# Pressure half-time



***PHT > 500 ms: IAo lieve***  
***PHT < 200 ms: IAo severa***

***Bassa capacità discriminante***

***PHT < 200 ms: elevata specificità  
per IAo severa (spesso acuta)***

- ***Influenzato da tutti i fattori che interferiscono con il gradiente Ao-VS***
- ***Jet eccentrici***



# Accuratezza dei metodi semiquantitativi


Threshold	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	AUC
<b>PHT ≤ 200 msec</b>					
Overall	12	100	100	52	0.73
Tricuspid valve	13	100	100	55	0.74
Bicuspid valve	10	100	100	40	0.72
<b>DFR ≥ 18 cm/sec</b>					
Overall	45	87	79	60	0.77
Tricuspid valve	38	85	69	61	0.74
Bicuspid valve	62	100	100	53	0.86
<b>VC ≥ 6 mm</b>					
Overall	81	83	78	85	0.89
Tricuspid valve	83	83	75	88	0.88
Bicuspid valve	78	81	86	72	0.89

Messika-Zeitoun D et al. J Am Soc Echocardiogr 2011; 24: 1246-52 (mod)




# Valutazione quantitativa

## Metodo 2D - Doppler



# Metodo PISA




**Tribouilloy CM et al. J Am Coll Cardiol 1998; 32: 1032-9**

**Pouleur AC et al. Am J Cardiol 2008; 102: 475-480**



# Metodo PISA



$$EROA = 2 \pi r^2 \times Va / Vmax \quad \geq 30 \text{ mm}^2$$
$$VR = EROA \times TVI \quad \geq 60 \text{ ml/b}$$



**European Association of Echocardiography  
recommendations for the assessment of valvular  
regurgitation. Part 1: aortic and pulmonary  
regurgitation (native valve disease)**

**When feasible, the PISA method is highly recommended to quantify the severity of AR. It can be used in both central and eccentric jets. In eccentric AR jets, we recommend to use the parasternal long-axis view to evaluate the flow convergence zone. An EROA  $\geq 30$  mm<sup>2</sup> or an R Vol  $\geq 60$  mL indicates severe AR.**



# Metodo PISA


- ***Stima quantitativa (validazione con RM)***
- ***Significato prognostico***
- ***Utilizzabile nei jet eccentrici***
- ***Non influenzato dalla frequenza cardiaca***
- ***Scarsa influenza dei fattori emodinamici***



# Metodo PISA

## Limiti

- **Fattibilità subottimale**
- **Variabilità interosservatore**
- **Errore elevato al quadrato**
- **Jet multipli**
- **Jet marcatamente eccentrici**
- **Orifizio rigurgitante non circolare**
- **Estese calcificazioni valvolari**
- **Aneurisma della radice aortica (angolo ottuso)**




# Gravità del rigurgito

Parametri	Grado di Insufficienza			
	Lieve	Moderato		Severo
Diametri e volumi del VS *	Normali	Normali o lievemente aumentati		Aumentati
Morfologia valvolare **	Normale/alterata	Normale/alterata		Alterata
Ampiezza della VC (mm)	< 3.0	3 ÷ 6		> 6
Ampiezza Jet / Diametro TEVS (%) ***	< 25	25 ÷ 64		≥ 65
Inversione del flusso in Ao discendente prossimale	Breve (solo in protodiastole) o assente	Intermedia o olodiastolica con v. telediastolica < 20 cm/sec		Olodiastolica con v. telediastolica > 20 cm/sec
Intensità del segnale	Incompleta o debole	Densa		Densa
PHT (msec)	> 500	500 ÷ 200		< 200
Area Jet/Area TEVS (%)	< 5	5 ÷ 59		≥ 60
VR (ml/b)	< 30	30 ÷ 44	45 ÷ 59	≥ 60
FR (%)	< 30	30 ÷ 40	40 ÷ 49	≥ 50
EROA (mm <sup>2</sup> )	< 10	10 ÷ 19	20 ÷ 29	≥ 30



# Flow chart



# *Color me variable: the irreproducible nature of color flow Doppler in aortic regurgitation*

***Always measure the blood pressure at the time of the echocardiogram and, if possible, throughout the examination. Post and update blood pressure with patient data so that it is accessible to the reader who is interpreting the digital loop or video clip.***



***Schiller NB. Am Heart J 2002; 144: 5-7***



# *Insufficienza aortica*


*Fisiopatologia*

*Gravità del rigurgito*

- ***Funzione ventricolare sinistra***

*Timing chirurgico*

# Impatto sul ventricolo sinistro




MI: 1.5  
S3  
22 NOV 11  
A+AREA 28.8 cm<sup>2</sup>  
CIRC. 22.7 cm  
DIST. 8.22 cm  
A.O. MOD-VOL 81.8 ml  
LIC:  
Adulti  
PE AN

2:27:41  
GUAD 50  
COMP 70  
67BPM

18CM  
25HZ

P 1.3 2.6  
0.92  
SEC



T# 10  
27

- *Diametri e volumi del VS*
- *Frazione d' eiezione del VS*



# Mortality in subgroups of patients

	Event rates		Linearized yearly rate (%/y)	p vs expected
	5 y	10 y		
<b>EF &lt; 55 %</b>	20 ± 9	47 ± 13	<b>5.8</b>	<b>0.03</b>
<b>EF ≥ 55 %</b>	10 ± 4	17 ± 5	2.0	0.81

## Independent predictor of survival

Excess mortality rate compared with expected rate was observed with **EF < 50 %** (at 10 years, 74 ± 10 %, p < 0.001) and with **EF of 50 to 55 %** (at 10 years, 35 ± 12 % , p = 0.039)




Dujardin KS et al.: *Circulation* 1999; 99: 1851-7



# Risk stratification based on LV dimension

<i>Variable</i>	<i>Value</i>	<i>Likelihood of death, symptoms, or LV dysfunction</i>
<b>LV end-systolic dimension</b>	<b>&gt; 50 mm</b>	19 % per year
	40-49 mm	6 % per year
	< 40 mm	0 % per year
<b>LV end-diastolic dimension</b>	<b>≥ 70 mm</b>	10 % per year
	< 70 mm	2 % per year



# *DTSVS indicizzato*



*Dujardin KS et al.: Circulation 1999; 99: 1851-7*




# VTSVS indicizzato





## Cardiac events:

- cardiac death
- congestive heart failure
- new atrial fibrillation

Detaint D et al. J Am Coll Cardiol Img. 2008; 1: 1-11 (mod.)



1	LVLs A4C	9.2 cm
	LVAs A4C	35.4 cm <sup>2</sup>
	LVESV A-L A4C	115 ml
	LVESV MOD A4C	111 ml
	HR	59 BPM



**DTSVS = 22 mm/m<sup>2</sup>**

60 HR

59 HR



**VTSVS = 57 ml/m<sup>2</sup>**

**VTDVS > 45 ml/m<sup>2</sup>: indicazione chirurgica**

*Detaint D et al. J Am Coll Cardiol Img. 2008; 1: 1-11*


# Funzione sistolica longitudinale

23/06/2012 12:00:27




23/06/2012 12:03:40

56  
HR




# Funzione sistolica longitudinale



**Velocità sistolica annulus laterale  
< 6.25 cm/sec**

**Predittivo di chirurgia entro 1 anno  
(sens: 97 %; spec: 83 %)**



**Paraskevaidis IA et al. AJC 2007; 100: 1677-82**

# Strain longitudinale

**Strain sistolico longitudinale globale significativamente inferiore nei pazienti con IAO severa e normale FE (- 17.5 ± 3.1 % vs - 22.1 ± 1.8 % p < 0.01)**

**Smedsrud MK et al. J Am Soc Echocardiogr 2011; 24: 1253-9**



**Table 3. Association Between Echocardiography and Outcome**

Baseline Measurement	Outcome During Conservative Management (n = 33)				Outcome After Surgery (n = 29)			
	Stable (n = 25)	Progression (n = 8)	OR (95% CI)	p Value	Good (n = 18)	Impaired (n = 11)	OR (95% CI)	p Value
Conventional echocardiography								
LVEF (%)	58.7 ± 5.4	57.6 ± 3.6	1.3 (0.6–3.0)	0.57	53.9 ± 9.8	45.2 ± 11.8	2.3 (1.1–6.1)	0.04
LVEDVI (ml/m <sup>2</sup> )	58.9 ± 16.4	64.9 ± 21.1	1.4 (0.6–3.5)	0.39	92.2 ± 24.8	119.7 ± 33.4	3.0 (1.2–10.7)	0.01
LVESVI (ml/m <sup>2</sup> )	24.2 ± 7.1	27.8 ± 10.2	1.6 (0.7–4.0)	0.26	43.6 ± 18.8	67.5 ± 27.7	3.2 (1.3–10.5)	0.01
Speckle tracking								
e <sub>sys</sub> (%)	-19.0 ± 2.6	-16.3 ± 3.3	3.2 (1.2–13.8)	0.02	-15.6 ± 2.3	-11.5 ± 4.3	3.7 (1.4–14.4)	0.006
SR <sub>sys</sub> (s <sup>-1</sup> )	-1.19 ± 0.17	-1.04 ± 0.14	3.3 (1.2–13.4)	0.02	-1.01 ± 0.17	-0.88 ± 0.19	2.6 (1.0–9.0)	0.04
SR <sub>dia</sub> (s <sup>-1</sup> )	1.60 ± 0.30	1.20 ± 0.34	4.6 (1.6–18.8)	0.002	1.33 ± 0.36	0.98 ± 0.21	4.0 (1.4–16.3)	0.005
Tissue Doppler								
LD <sub>sys</sub> (mm)	11.2 ± 1.8	10.7 ± 2.1	1.4 (0.6–3.3)	0.45	11.2 ± 2.4	8.9 ± 2.5	2.8 (1.2–8.0)	0.02
s' (cm/s)	6.0 ± 1.1	5.5 ± 0.6	1.9 (0.8–5.4)	0.14	5.8 ± 0.8	4.9 ± 1.2	2.9 (1.2–9.4)	0.02
e' (cm/s)	-6.5 ± 2.1	-5.9 ± 1.8	1.4 (0.6–3.4)	0.46	-6.2 ± 2.4	-5.0 ± 2.0	1.8 (0.8–4.9)	0.17

Data are expressed as mean ± SD.  
CI = confidence interval; OR = odds ratio associated with 1 SD of worsening in predictive measure; other abbreviations as in Table 2.

**Strain predittivo di progressione della malattia (sintomi, incremento del volume VS > 15 %, riduzione della frazione d' eiezione > 10 %)**

**Olsen NT et al. J Am Coll Cardiol Img 2011; 4: 223-30**



# *Insufficienza aortica*


*Fisiopatologia*


*Gravità del rigurgito*

*Funzione ventricolare sinistra*

- *Timing chirurgico*

# Guidelines on the management of valvular heart disease (version 2012)






# Echocardiography in aortic diseases: EAE recommendations for clinical practice

Arturo Evangelista<sup>1\*</sup>, Frank A. Flachskampf<sup>2</sup>, Raimund Erbel<sup>3</sup>,  
Francesco Antonini-Canterin<sup>4</sup>, Charalambos Vlachopoulos<sup>5</sup>, Guido Rocchi<sup>6</sup>,  
Rosa Sicari<sup>7</sup>, Petros Nihoyannopoulos<sup>8</sup>, and Jose Zamorano<sup>9</sup> on behalf of the  
European Association of Echocardiography

## Recommendation

TTE permits adequate assessment of several aortic segments, particularly the aortic root and proximal ascending aorta. All scanning planes should be used to obtain information on most aortic segments. However, if inconclusive information or abnormalities are present, another imaging modality is required to either complete or add diagnostic information.

***Evangelista A et al. : Eur J Echocardiogr 2010; 11: 645-658***



# *Dimensioni aortiche*

- ***Ecocardiografia transtoracica bidimensionale***
- ***Misurazione in telediastole utilizzando la sezione che consente di visualizzare la dimensione massima del segmento in esame***
- ***Utilizzazione di sezioni ecocardiografiche non convenzionali (parasternale sinistra alta, parasternali destre)***
- ***Asse perpendicolare all' asse lungo del vaso***
- ***Può essere utilizzata sia la misurazione "leading edge to leading edge" che quella "inner edge to inner edge" (specificare)***
- ***Indicizzazione delle dimensioni aortiche (SC, altezza)***



# TC e RM

## Classe I

*La RM o la TC sono indicate quando non é possibile ottenere con l'ecocardiografia un'adeguata valutazione della radice aortica e dell'aorta ascendente (livello di evidenza C)*

## Classe IIa

*La RM o la TC sono consigliate, per una più completa valutazione, nei pazienti con dilatazione della radice aortica e/o dell'aorta ascendente ed indicazione o possibile indicazione alla chirurgia dell'aorta (livello di evidenza B)*



# Guidelines on the management of valvular heart disease (version 2012)

**Table 8** Indications for surgery in (A) severe aortic regurgitation and (B) aortic root disease (whatever the severity of aortic regurgitation)

	Class <sup>a</sup>	Level <sup>b</sup>	Ref <sup>c</sup>
<b>A. Indications for surgery in severe aortic regurgitation</b>			
Surgery is indicated in symptomatic patients.	I	B	59
Surgery is indicated in asymptomatic patients with resting LVEF ≤50%.	I	B	71
Surgery is indicated in patients undergoing CABG or surgery of ascending aorta, or on another valve.	I	C	
Surgery should be considered in asymptomatic patients with resting EF >50% with severe LV dilatation: LVEDD >70 mm, or LVESD >50 mm or LVESD >25 mm/m <sup>2</sup> BSA. <sup>d</sup>	IIa	C	
<b>B. Indications for surgery in aortic root disease (whatever the severity of AR)</b>			
Surgery is indicated in patients who have aortic root disease with maximal ascending aortic diameter <sup>e</sup> ≥50 mm for patients with Marfan syndrome.	I	C	

<sup>f</sup>Family history of aortic dissection and/or aortic size increase >2 mm/year (on repeated measurements using the same imaging technique, measured at the same aorta level with side-by-side comparison and confirmed by another technique), severe AR or mitral regurgitation, desire of pregnancy.

<sup>g</sup>Coarctation of the aorta, systemic hypertension, family history of dissection or increase in aortic diameter >2 mm/year (on repeated measurements using the same imaging technique, measured at the same aorta level with side-by-side comparison and confirmed by another technique).




# Guidelines on the management of valvular heart disease (version 2012)

**Table 8** Indications for surgery in (A) severe aortic regurgitation and (B) aortic root disease (whatever the severity of aortic regurgitation)


	Class <sup>a</sup>	Level <sup>b</sup>	Ref <sup>c</sup>
<b>A. Indications for surgery in severe aortic regurgitation</b>			
Surgery is indicated in symptomatic patients.	I	B	59
Surgery is indicated in asymptomatic patients with resting LVEF ≤50%.	I	B	71
Surgery is indicated in patients undergoing CABG or surgery of ascending aorta, or on another valve.	I	C	
Surgery should be considered in asymptomatic patients with resting EF >50% with severe LV dilatation: LVEDD >70 mm, or LVESD >50 mm or LVESD >25 mm/m <sup>2</sup> BSA. <sup>d</sup>	IIa	C	
<b>B. Indications for surgery in aortic root disease (whatever the severity of AR)</b>			
Surgery is indicated in patients who have aortic root disease with maximal ascending aortic diameter <sup>e</sup> ≥50 mm for patients with Marfan syndrome.			
Surgery should be considered in patients who have aortic root disease with maximal ascending aortic diameter: ≥45 mm for patients with Marfan syndrome with risk factors <sup>f</sup> ≥50 mm for patients with bicuspid valve with risk factors <sup>g</sup> ≥55 mm for other patients	IIa	C	

***VTSVS ≥ 45 ml/m<sup>2</sup>***



# Peptidi natriuretici

294 pazienti asintomatici; FEVS > 55 %



**DVS, sintomi, morte**

Endpoint	OR (95% CI)	p Value
BNP ≥130 pg/ml	6.9 (2.52-17.57)	0.0001
ESD/BSA ≥24 mm/m <sup>2</sup>	3.4 (1.88-11.9)	0.01
EROA ≥50 mm <sup>2</sup>	4.3 (2.4-12.4)	0.001
EDD ≥35 mm/m <sup>2</sup>	2.1 (0.88-13.7)	0.09



# ***Insufficienza aortica severa***

## ***Età dei pazienti***


	<b><i>n. pz</i></b>	<b><i>Età</i></b>
<b><i>Dujardin et al. (1999)</i></b>	<b>246</b>	<b>56 ± 19</b>
<b><i>Corti et al. (2001)</i></b>	<b>125</b>	<b>44 ± 13</b>
<b><i>Chukwuemeka et al. (2006)</i></b>	<b>72</b>	<b>59 ± 12</b>
<b><i>Detaint et al. (2008)</i></b>	<b>93</b>	<b>58 ± 18</b>
<b><i>Kamath et al. (2009)*</i></b>	<b>166*</b>	<b>65 ± 16*</b>
<b><i>Turk et al. (2010)</i></b>	<b>123</b>	<b>60 ± 17</b>
<b><i>Olsen et al. (2011)</i></b>	<b>64</b>	<b>57 ± 13</b>

**\*FEVS ≤ 35 %**



# Disfunzione ventricolare sinistra


Survival curves in patients with EF  $\leq 35\%$



Number at risk

	0	2	4	6	8	10
AVR	53	36	29	8	7	7
No AVR	113	50	34	30	19	9


Survival curves in patients with EF  $\leq 20\%$




Number at risk

	0	1	2	3	4	5	6
AVR	21		15		13		5
No AVR	57		23		16		12





**17 febbraio 2012**



**26 aprile 2012**

# *Insufficienza aortica - TAVI*

